Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
Integrated BioPharma, Inc. (INBP) filed its definitive proxy and set the 2025 Annual Meeting for December 1, 2025 at 9:00 a.m. local time at its Hillside, NJ offices. Stockholders will vote on: (1) electing Class III director nominee Eric Friedman for a three-year term; (2) a non-binding advisory vote on executive compensation (say‑on‑pay); (3) a non-binding advisory vote on the frequency of say‑on‑pay; and (4) ratifying CBIZ CPAs P.C. as independent auditor for the fiscal year ending June 30, 2026.
The Board unanimously recommends FOR the director nominee, FOR say‑on‑pay, THREE YEARS for say‑on‑pay frequency, and FOR auditor ratification. Holders of record as of October 17, 2025 may vote; 31,059,610 shares of common stock were outstanding on the record date. Proxy materials are available at materials.proxyvote.com/45811V.
Integrated Biopharma, Inc. filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The company clarifies the furnished information is not "filed" for Section 18 liability purposes and has attached the exhibit in Item 9.01.
Integrated BioPharma, Inc. (INBP) reports consolidated fiscal-year information and disclosures for the year ended June 30, 2025. The company states it has a cybersecurity program based on recognized standards and is not aware of any cybersecurity incidents that have materially affected its business. The balance sheet notes 50,000,000 shares authorized and roughly 31.1 million shares outstanding reported in the filing. The company recorded a $20 allowance for credit losses at June 30, 2025 (versus $1 at June 30, 2024). Two customers accounted for approximately 84% of consolidated net sales in 2025 and represented about 76% of accounts receivable at June 30, 2025. The filing discloses federal and state NOLs with limited realizability and a valuation allowance changes: a $830 reserve recorded against federal NOL-related deferred tax assets and a $347 release of the state NOL valuation reserve due to tax law change. Lease amendments and stock option plan details (plans with 4,659,652 shares remaining; recent option grants and exercise prices) are included, and a finance lease obligation of $485 due to a related party is disclosed.